Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

PHVS vs NTLA: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

PHVS Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 5–2 Matrix Metrics)

PHVS Overall Winner 6-Pillar Tally: PHVS 4 – 2 NTLA Matrix Metrics: PHVS 5 – 2 NTLA

As of Nov 16, 2026, Pharvaris N.V. (PHVS) is the stronger overall head-to-head candidate over Intellia Therapeutics, Inc (NTLA) in the Tradestie Institutional Equity Comparison Engine, winning 5–2 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). PHVS carries a Unified Composite Score of 37.6/100 (SELL) at $32.61 (N/M Forward P/E, 0.0% operating margin), whereas NTLA carries 50.7/100 (HOLD) at $10.00 (N/M Forward P/E, -826.0% operating margin).

  • Composite vs. Pillar Nuance: While NTLA currently prints a higher short-term Unified Composite Score (50.7/100 HOLD vs. PHVS 37.6/100 SELL), PHVS captures the overall institutional head-to-head verdict (5–2 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -826.0% operating margin) and revenue trajectory (+0.0% vs. -48.0% YoY).
  • Technical & Structure Timing Caution: PHVS is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 47.7); meanwhile NTLA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 39.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About PHVS vs NTLA
PHVS NASDAQ Head-to-Head Winner
Pharvaris N.V. Ordinary Shares
Pharmaceutical Preparations
$32.61
-2.25% 1D
Market Cap $2.4B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.67β · 38% Vol
Unified Composite Score
37.6 / 100 SELL
Tech 35.0 Fund 47.0 Flow 58.0 Mom 50.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope -3.2%) with fading momentum, RSI 48
RSI-14: 47.7 · SMA20: $32.95 · SMA50: $33.19
NTLA NASDAQ
Intellia Therapeutics, Inc
In Vitro & In Vivo Diagnostic Substances
$10.00
+3.09% 1D
Market Cap $1.5B
TTM Revenue $53M
Forward P/E N/M
Beta / 30D Vol 2.30β · 87% Vol
Unified Composite Score
50.7 / 100 HOLD
Tech 47.0 Fund 55.0 Flow 59.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -3.2%), weak momentum, RSI 39
RSI-14: 39.0 · SMA20: $11.58 · SMA50: $11.86

6-Pillar Scorecard Institutional Category Breakdown (PHVS 4 – 2 NTLA)

Columns: Metric · PHVS · NTLA
1. Valuation Multiples NTLA
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M 29.1x
2. Growth & Scale PHVS
Revenue Growth (YoY) +0.0% -48.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $53M
Market Cap $2.4B $1.5B
3. Profitability & Quality PHVS
Gross Margin N/A N/A
Operating Margin 0.0% -826.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -70.5% -62.6%
4. Balance Sheet & Cash Flow PHVS
Cash Generation (TTM) -$167M -$358M
Cash Flow Margin N/A N/A
Net Cash / Leverage $282M Net Cash $74M Net Debt (0.38x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning PHVS
Options Structure Phase CONSOLIDATION BREAKDOWN
Current IV / %ile 81.1% (7th %ile) 101.3% (78th %ile)
Put/Call OI Skew 1.15x (Put-Skewed) 0.42x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Distribution DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat NTLA
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: PHVS (5) vs NTLA (2)
Institutional Metric PHVS NTLA Criterion Row Edge
Market Capitalization
Scale
$2.4B $1.5B Larger Scale PHVS
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% -48.0% Higher Growth PHVS
Operating Margin (TTM)
Profitability
0.0% -826.0% Higher Margin PHVS
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-70.5% -62.6% Higher ROE NTLA
52-Week Range Position
Momentum
48% ($23–$43) 20% ($8–$18) Stronger Trend PHVS
Beta / 30D Volatility
Risk Regime
0.67β · 38% Vol 2.30β · 87% Vol Lower Realized Risk PHVS
Unified Institutional Score
Composite Signal
37.6 / 100 (SELL) 50.7 / 100 (HOLD) Higher Composite NTLA
Trailing 12M Revenue (USD)
Operating Scale
N/A $53M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 29.1x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$167M ($282M Net Cash) -$358M ($74M Net Debt (0.38x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon PHVS +29.99 pp
PHVS: +17.56% · NTLA: -12.43%
3M Horizon PHVS +4.12 pp
PHVS: -9.67% · NTLA: -13.79%
6M Horizon PHVS +34.39 pp
PHVS: +13.19% · NTLA: -21.2%
1Y Horizon PHVS +19.08 pp
PHVS: +34.42% · NTLA: +15.34%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on PHVS vs NTLA. Trailing 12-month operating profitability (PHVS 0.0% vs NTLA -826.0%) and valuation multiples (PHVS N/M vs NTLA N/M Forward P/E) are benchmarked directly in Pillar 4 below.

PHVS ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-70.5% · N/M
NTLA ADR TTM Benchmark FX-Normalized USD
TTM Revenue$53M
Gross MarginN/A
Op. Margin-826.0%
ROE / Fwd P/E-62.6% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
PHVS CONSOLIDATION
105d in phase · OBV NEUTRAL
Current IV 81.1%
IV Percentile 7th %ile
Put/Call OI Skew 1.15x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow NEUTRAL
Exact PHVS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
NTLA BREAKDOWN
94d in phase · OBV DISTRIBUTION
Current IV 101.3%
IV Percentile 78th %ile
Put/Call OI Skew 0.42x (Call-Skewed)
IV Regime Elevated (60th–80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact NTLA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
PHVS Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $2.4B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
NTLA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.5B market capitalization and -826.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published · CRISPR / Gene Editing

Investor FAQ PHVS vs NTLA Key Questions & Quantitative Answers

As of Nov 16, 2026, Pharvaris N.V. (PHVS) is the stronger overall head-to-head candidate over Intellia Therapeutics, Inc (NTLA) in the Tradestie Institutional Equity Comparison Engine, winning 5–2 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). PHVS carries a Unified Composite Score of 37.6/100 (SELL) at $32.61 (N/M Forward P/E, 0.0% operating margin), whereas NTLA carries 50.7/100 (HOLD) at $10.00 (N/M Forward P/E, -826.0% operating margin). Composite vs. Pillar Nuance: While NTLA currently prints a higher short-term Unified Composite Score (50.7/100 HOLD vs. PHVS 37.6/100 SELL), PHVS captures the overall institutional head-to-head verdict (5–2 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -826.0% operating margin) and revenue trajectory (+0.0% vs. -48.0% YoY). Technical & Structure Timing Caution: PHVS is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 47.7); meanwhile NTLA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 39.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

PHVS leads the Growth & Scale pillar: PHVS posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with NTLA at -48.0% YoY revenue growth and +0.0% YoY earnings growth on $53M TTM revenue (N/A gross margin, -826.0% operating margin). On trailing 12-month operating scale, PHVS generates N/A in USD-normalized revenue versus $53M for NTLA. In operating R&D and SG&A reinvestment, PHVS deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for NTLA.

NTLA screens cheaper on headline valuation multiples. PHVS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas NTLA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 29.1x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against PHVS (-70.5% ROE) versus NTLA (-62.6% ROE) capital efficiency.

In options market volatility and institutional positioning, PHVS carries 81.1% implied volatility (7th %ile, Compressed (<25th %ile)), a 1.15x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (0.67β · 38% Vol realized risk). By comparison, NTLA carries 101.3% implied volatility (78th %ile, Elevated (60th–80th %ile)), a 0.42x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (2.30β · 87% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.